Show simple item record

2021-05-21Zeitschriftenartikel
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
dc.contributor.authorMaisa, Anna
dc.contributor.authorKollan, Christian
dc.contributor.authoran der Heiden, Matthias
dc.contributor.authorvan Bömmel, Florian
dc.contributor.authorCornberg, Markus
dc.contributor.authorMauss, Stefan
dc.contributor.authorWedemeyer, Heiner
dc.contributor.authorSchmidt, Daniel
dc.contributor.authorDudareva, Sandra
dc.date.accessioned2022-02-01T12:29:28Z
dc.date.available2022-02-01T12:29:28Z
dc.date.issued2021-05-21none
dc.identifier.other10.3389/fpubh.2021.667253
dc.identifier.urihttp://edoc.rki.de/176904/9316
dc.description.abstractBackground: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the treatment costs within the statutory health insurance (SHI) in Germany and per patient per month. Methods: Data on pharmacy bills of NUCs to patients with SHI between 2008 and 2019 were purchased from Insight Health™ and described. Negative binomial regression was used for trend analysis. Results: Number of patients increased between 2008 and 2019 (4.9% per year) with little changes in treatment options. Overall prescription costs were increasing (6.7% per year on average) until the introduction of tenofovir and entecavir generics in 2017 after which costs decreased by 31% in 2019. Average therapy costs peaked at 498 Euro per patient per month in 2016 and decreased to 214 Euro in 2019. Prescriptions changed from 30 to 90 pills per pack over time. HBV therapy was prescribed to 97% by three medical specialist groups, mainly specialists in internal medicine (63%), followed by hospital-based outpatient clinics (20%) and general practitioners (15%). Contrary to guideline recommendation, adefovir was still prescribed after 2011 for 1–5% of patients albeit with decreasing tendency. Prescriptions per 100,000 inhabitants were highest in Berlin and Hamburg. Conclusion: Our data shows, that the number of treated CHB patients increased steadily, while NUC therapy costs decreased. We recommend continued testing and treatment for those eligible to prevent advanced liver disease and possibly decrease further transmission of HBV.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjecthepatitis Beng
dc.subjectnucleos(t)ide therapyeng
dc.subjecttherapy costseng
dc.subjecttreatment guidelineseng
dc.subjecttreatment gapeng
dc.subjecthepatitis eliminationeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleIncreasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019none
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/9316-0
dc.type.versionpublishedVersionnone
local.edoc.container-titlePublic Healthnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.frontiersin.org/articles/10.3389/fpubh.2021.667253/fullnone
local.edoc.container-publisher-nameFrontiersnone
local.edoc.container-volume9none
local.edoc.container-year2021none
local.edoc.container-firstpage1none
local.edoc.container-lastpage7none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Show simple item record